ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

DETERMINING THE LEVEL OF PATIENTS WITH HEPATITIS B TREATMENT TO MEET LIVER BIOPSY CRITERIA

Dr Umer Farooq, Dr Hamza Ahmad, Dr Ali Shayyan

Aim: Lebanon has recently been considered the low endemic country for constant hepatitis B. The purpose of the current research was to achieve METAVIR score by Persistent Ag through hepatitis B and e negatives, which did not meet the close and universal healing standards, which have HBVDNA > 2500 IU/mL, through a typical or somewhat higher ALT level. Methods: Our research was conducted at Mayo Hospital, Lahore from November 2017 to October 2018. We check each liver biopsy performed in last 3 years in a calm environment with incessant hepatitis B, HBeAg negative, HBV DNA > 2000IU/ml and ALT in the typical range. The information composed was characterized and transmitted by the METAVIR rating framework for fibrosis and movement, then divided by age, gender and every conceivable relationship among aggravation and fibrosis. Results: The total of 260 liver biopsies were observed throughout this period; only 48 biopsies responded to the incorporation criteria. The circulation of liver biopsies identified with age show that 68% of patients were somewhere in the age range of 23 and 41 years, there is a transcendence of men. The spread of hepatic biopsies identified with incessant hepatitis B according to the METAVIR score shows that 29.87% of them had propelled fibrosis (organize F2 or extra or potentially action A2 or more). Conclusion: This examination shows standing of liver biopsy in cases with incessant hepatitis B, HBeAg negative and shows that 31% of the current populace requires drug healing for progressive liver disease. Key words: Liver biopsy; ALT; HBeAg negative; Healing suggestion.

FULL TEXT